Journal article
Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: Results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis)
Abstract
BACKGROUND: Vasoflux is a low-molecular-weight heparin derivative that inhibits factor IXa activation of factor X and catalyzes fibrin-bound thrombin inactivation by heparin cofactor II. We studied whether vasoflux improves the results of thrombolysis with streptokinase for acute myocardial infarction.
METHODS AND RESULTS: We randomized 277 patients with acute myocardial infarction to standard intravenous unfractionated heparin (UFH) or …
Authors
Peters RJG; Spickler W; Théroux P; White H; Gibson M; Molhoek PG; Anderson HV; Weitz JI; Hirsh J; Weaver WD
Journal
American Heart Journal, Vol. 142, No. 2, pp. 237–243
Publisher
Elsevier
Publication Date
August 2001
DOI
10.1067/mhj.2001.116759
ISSN
0002-8703
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAnticoagulantsAspirinCanadaCoronary AngiographyDose-Response Relationship, DrugDrug Therapy, CombinationFemaleFibrinolytic AgentsHeparinHumansInfusions, IntravenousMaleMiddle AgedMyocardial InfarctionNetherlandsNew ZealandSingle-Blind MethodStreptokinaseThrombolytic TherapyTreatment OutcomeUnited States